| General Information | |
|---|---|
| ZINC ID | ZINC000045497330 |
| Molecular Weight (Da) | 492 |
| SMILES | C[C@H](O)c1c(-c2nnc(C(C)(C)C)o2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1 |
| Molecular Formula | C23Cl3N4O2 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 128.619 |
| HBA | 5 |
| HBD | 1 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 32 |
| LogP | 6.834 |
| Activity (Ki) in nM | 10 |
| Polar Surface Area (PSA) | 76.97 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.854 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 22 |
| Fraction csp3 | 0.26 |
| Ilogp | 4.34 |
| Xlogp3 | 6.19 |
| Wlogp | 6.58 |
| Mlogp | 4.77 |
| Silicos-it log p | 6.17 |
| Consensus log p | 5.61 |
| Esol log s | -6.97 |
| Esol solubility (mg/ml) | 0.000053 |
| Esol solubility (mol/l) | 0.0000001 |
| Esol class | Poorly sol |
| Ali log s | -7.59 |
| Ali solubility (mg/ml) | 0.0000126 |
| Ali solubility (mol/l) | 2.56E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -9.18 |
| Silicos-it solubility (mg/ml) | 0.00000032 |
| Silicos-it solubility (mol/l) | 6.61E-10 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.91 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 2 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 4.26 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.942 |
| Logd | 4.274 |
| Logp | 5.435 |
| F (20%) | 0.002 |
| F (30%) | 0.002 |
| Mdck | - |
| Ppb | 98.34% |
| Vdss | 2.383 |
| Fu | 1.85% |
| Cyp1a2-inh | 0.369 |
| Cyp1a2-sub | 0.708 |
| Cyp2c19-inh | 0.878 |
| Cyp2c19-sub | 0.091 |
| Cl | 4.356 |
| T12 | 0.039 |
| H-ht | 0.334 |
| Dili | 0.979 |
| Roa | 0.195 |
| Fdamdd | 0.685 |
| Skinsen | 0.036 |
| Ec | 0.003 |
| Ei | 0.01 |
| Respiratory | 0.831 |
| Bcf | 2.382 |
| Igc50 | 4.962 |
| Lc50 | 6.611 |
| Lc50dm | 5.071 |
| Nr-ar | 0.004 |
| Nr-ar-lbd | 0.208 |
| Nr-ahr | 0.097 |
| Nr-aromatase | 0.947 |
| Nr-er | 0.898 |
| Nr-er-lbd | 0.659 |
| Nr-ppar-gamma | 0.834 |
| Sr-are | 0.932 |
| Sr-atad5 | 0.022 |
| Sr-hse | 0.057 |
| Sr-mmp | 0.955 |
| Sr-p53 | 0.9 |
| Vol | 452.974 |
| Dense | 1.082 |
| Flex | 0.227 |
| Nstereo | 1 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 3 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.336 |
| Synth | 3.188 |
| Fsp3 | 0.261 |
| Mce-18 | 54 |
| Natural product-likeness | -1.142 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |